Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
-0.42 (-0.27%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 154.79 - 156.13
52 week 133.64 - 184.21
Open 155.60
Vol / Avg. 2.73M/3.16M
Mkt cap 113.69B
P/E 14.69
Div/yield 1.15/2.97
EPS 10.55
Shares 735.40M
Beta 1.28
Inst. own 81%
May 19, 2017
Amgen Inc Annual Shareholders Meeting
May 17, 2017
Amgen Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
Apr 26, 2017
Q1 2017 Amgen Inc Earnings Call - Webcast
Apr 26, 2017
Q1 2017 Amgen Inc Earnings Release
Mar 21, 2017
Amgen Inc at Oppenheimer Healthcare Conference
Mar 17, 2017
Amgen Inc Investor Meeting at American College of Cardiology 66th Annual Scientific Session - Webcast
Mar 8, 2017
Amgen Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 37.90% 33.59%
Operating margin 47.42% 42.60%
EBITD margin - 51.79%
Return on average assets 10.68% 10.36%
Return on average equity 27.45% 26.65%
Employees 19,200 -
CDP Score - C


1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 62
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 60
Bio & Compensation  - Reuters
Esteban Santos Executive Vice President, Operations
Age: 49
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 55
Bio & Compensation  - Reuters
Jonathan P. Graham Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Lori A. Johnston Senior Vice President
Age: 52
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters